Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Alejandro Berkovits"'
Autor:
Miguel Cordova-Delgado, Mauricio P. Pinto, Gonzalo Pizarro, Elard Koch, Cristian Vargas, Mauricio Hernández, Guillermo Nourdin, Pablo Saldivia, Maria Paz Rodriguez Z., Alejandro Berkovits, Patricio Manque, Juvenal A. Rios, Benjamin Garcia-Bloj, Marcelo Garrido
Publikováno v:
Journal of Gastrointestinal Oncology. 13:2057-2064
Autor:
Alejandro Berkovits, Eduardo Yanez, Christine Rojas, Raimundo Gazitua, Nicolás Cazap, Anna Sureda, Rao Saleem, Robin Meng, Jing Xu, Michael Streit, Valentine Barboux, Sairah Ahmed
Publikováno v:
Blood. 140:12020-12021
Autor:
Miguel Cordova-Delgado, Mauricio P. Pinto, Carlos Regonesi, Luis Cereceda, José Miguel Reyes, Laura Itriago, Alejandro Majlis, Pablo Rodríguez, André Fassler, Mauricio Mahave, María Elisa León, Jorge Gallardo, María Paz Rodríguez Z., Alejandro Berkovits, Patricio Manque, Juvenal A. Ríos, Benjamín Garcia-Bloj, Marcelo Garrido
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 2; Pages: 195
Major advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and “biomarker-driven” treatments. However, the impact of this approach on the everyday clinic has
Autor:
Matías Muñoz-Medel, Miguel Córdova-Delgado, Ignacio N. Retamal, Fabián Villalobos, Rosemarie Mellado, Piga Fernández, Patricio Manque, Alejandro Berkovits, Juvenal A. Ríos, Benjamín García-Bloj, María Paz Rodríguez, Marcelo Garrido
Publikováno v:
Gastrointestinal Stromal Tumor. 5:6-6
Autor:
Mauricio P. Pinto, Matias Muñoz Medel, Miguel Córdova Delgado, Ignacio N. Retamal, Patricio Manque, Alejandro Berkovits, Maria Paz Rodriguez, Juvenal A. Rios, Benjamin Garcia-Bloj, Gareth Owen, Marcelo Garrido
Publikováno v:
Cancer Research. 82:1969-1969
Background: Gastric cancer (GC) is the leading cause of cancer death in Chile, claiming >3,000 lives per year. On April 2021, the US Food and Drug Administration approved the combined use of Nivolumab (immunotherapy) plus chemotherapy as frontline tr
Autor:
Diego Mezzano, Alejandro Berkovits
Publikováno v:
Revista chilena de cardiología v.36 n.3 2017
SciELO Chile
CONICYT Chile
instacron:CONICYT
SciELO Chile
CONICYT Chile
instacron:CONICYT
Resumen: Los anticoagulantes orales clásicos del tipo cumarinas han estado disponibles para uso clínico por más de medio siglo. Tienen gran eficacia para tratar o prevenir trombosis y tromboembolias, y son drogas cuyo uso ha aumentado con el mejor
Autor:
Maria Pia De La Maza, Pablo Alvayay, Claudio Silva, Paula von Geldern, Claudio Salas, Alejandro Berkovits
Publikováno v:
Journal of Clinical Oncology. 37:e18290-e18290
e18290 Background: Detection and prevention of cancer cachexia during oncologic treatment is an important issue in cancer patients care. AIM: To analyze the relation between overall survival and nutritional status assessed both by subjective and obje
Publikováno v:
Expert review of hematology. 9(7)
Diffuse large B-cell lymphoma (DLBCL) is a molecularly heterogeneous disease defined by different cellular origins and mechanisms of oncogenic activation. Approximately 10% of DLBCL cases harbor a MYC rearrangement and this has been associated with a
Publikováno v:
Revista médica de Chile v.143 n.11 2015
SciELO Chile
CONICYT Chile
instacron:CONICYT
SciELO Chile
CONICYT Chile
instacron:CONICYT
Bleeding disorders are commonly associated with hemato-oncologic diseases. We report a 68 years old male with a chronic myelomonocytic leukemia derived from a long lasting mielodysplastic syndrome that did not respond to treatment with Azacitidine. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7191b4680875aecccddc71073448f3d1
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015001100016
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015001100016
Publikováno v:
Revista medica de Chile. 139(10)
Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide